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Probing the release of the chronobiotic hormone melatonin 
from hybrid calcium alginate hydrogel beads
A variety of commonly used hydrogels were utilized in the 
preparation of calcium alginate beads, which incorporate 
the chronobiotic hormone melatonin (MLT). The in vitro 
release of the hormone in aqueous media at pH 1.2 and 6.8 
was probed in the conjunction with the swelling of the 
beads and their thermal degradation properties. It has been 
found that the release of MLT from the beads was rever-
sibly proportional to the extent of their expansion, which 
depends on the molecular mass/viscosity of the biopoly-
mers present in the beads; the higher the molecular mass/
viscosity of the hydrogels the greater the beads swelling 
and the less the MLT’s release. Thermogravimetric analysis 
(TGA) data support the presence of the components in the 
hybrid hydrogel beads and elucidate their effects on the 
thermal stability of the systems. Thus, the physicochemical 
properties of the biopolymers used, along with their stereo-
electronic features modulate the release of MLT from the 
beads, providing formulations able to treat sleep onset re-
lated problems or dysfunctions arising from poor sleep 
maintenance.
Keywords: melatonin, hydrogels, calcium alginate beads, 
swelling behavior, thermogravimetric analysis, in vitro 
 release
Melatonin (N-acetyl-5-methoxytryptamine, MLT) is a hormone synthesized from the 
biogenic amine serotonin in the pineal gland (1). Norepinephrine also plays an important 
role in the production and the release of MLT, which is influenced by exposure to light (2). 
In addition, the necessary enzymes for the biosynthesis of MLT remain inactive in daylight 
and are activated during the night hours (3). The actions of MLT are associated with its 
binding to G-protein-coupled cell membrane receptors. So far, three different types of 
MLT’s receptors have been characterized (MT1, MT2 and MT3) (4). MLT, a hormone in-
volved in the regulation of the circadian rhythms, has therapeutic value in some blind 
subjects, restoring their disturbed circadian cycle (5). It also has a positive impact on the 
treatment of seasonal affective disorders (SAD), which afflict some people during the winter 
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also been implicated in a range of other diseases, including Parkinson’s disease (8), Al-
zheimer’s disease and other neurodegenerative conditions (9), and in various cancers (10). 
It has also been reported to be a potent antioxidant (11).
We have been interested in the development of dosage form products, which mimic 
the physiologically secreted high MLT levels at night, necessary to promote sleep onset 
and maintain sleep (12). Sleep dysfunctions, referring to sleep onset difficulties, are better 
treated with fast release MLT products, whilst those related to sleep maintenance prob-
lems are preferably treated with MLT modified release formulations (13–21). In this report 
we communicate our findings on the in vitro release of MLT from calcium alginate (CA) 
hydrogel beads, containing combinations of polyvinylpyrrolidone (PVP10000 and PVP55000), 
hydroxypropylmethylcellulose (HPMC15000 and HPMC100000), lactose monohydrate and as 
a surfactant sodium lauryl sulfate (SLS).
Beads are used for the modified release of vaccines, antibiotics, hormones and other 
drugs of diverse structures, as they provide large surface areas and possess an easier esti-
mation of diffusion and mass transfer behavior. Furthermore, polymeric beads show high 
bioavailability and stability. Other advantages include limited fluctuation in the therapeutic 
range, reduced side effects, decreased dosing frequency and improved patient compliance 
(21, 22). Moreover, the swelling behavior in conditions, like those of gastrointestinal liq-
uids, is a very important parameter that has to be investigated during the development of 
these systems for the oral administration of drugs (23). These compelling characteristics of 
the beads intrigued us to utilize them in our attempt to develop MLT formulations that can 
either treat sleep onset or poor sleep maintenance related problems. It was found that the 
higher the molecular mass/viscosity of the biopolymer, used in the construction of the 
beads, the higher their expansion leading to lower and prolonged MLT release. Thus, the 
physicochemical properties of the hydrogel used can modulate the release of MLT from 
the CA beads, resulting to formulations that have the potential to treat sleep onset related 
problems formulations (CA:PVP10000, CA:PVP10000:HPMC15000 1, CA:PVP55000, CA:Lactose and 
CA:PVP10000:Lactose) and to formulations suitable for alleviating sleep maintenance dys-
functions formulations (CA:HPMC15000, CA:PVP10000:HPMC15000 2, CA:PVP55000:HPMC15000, 
CA:HPMC100000).
To the best of our knowledge, this is the first report in the literature, where CA beads 
and mixtures of polymers are used for the encapsulation of MLT. The prepared systems 
were found to be suitable for the pH-responsive release of MLT in a manner strongly 
 dependent on the formulation of the systems. This study could serve as a roadmap for the 
design and development of formulations with controlled-release properties.
EXPERIMENTAL
Materials
All of the materials were of analytical grade and used as received without further 
purification. In detail, MLT (Mr = 232.28; melting point 117 °C, solubility in water 2 g L–1 at 
20 °C and 5 g L–1 at 50 °C and octanol/water partition coefficient 1.6) was purchased from 
the MP Biomedicals LLC (France). Low viscosity (250 mPa s of 2 % solution) alginic acid 
sodium salt (NaAlg) and calcium chloride dihydrate (CaCl2 × 2 H2O) were purchased from 
Sigma-Aldrich (USA). Furthermore, the simulated gastric fluid (SGF, pH 1.2) and the simu-
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lated intestinal fluid (SIF, pH 6.8) were prepared as described in the USP29-NF24 Pharma-
copeia (24). Macrogol 400 (PEG 4000) was given by Fagron Hellas (Greece) and lactose 
monohydrate was obtained from Merck. Polyvinylpyrrolidone (PVP10000, low Mw and 
PVP55000, high Mw), hydroxypropylmethylcellulose (HPMC15000, low Mw and HPMC100000, 
high Mw) and sodium lauryl sulfate were purchased from Sigma-Aldrich. All of these 
materials were of analytical grade and used as received without further purification.
Preparation of CA MLT beads
MLT (2 mg) was dissolved in a solution containing 0.4 mL PEG 4000, 0.6 mL H2O and 
0.025 mg of SLS, and then added to the alginate solution (vide infra).
The protocol reported by Pasparakis et al. (25), was followed for the preparation of the 
CA beads. Detailed experimental for the formation of the particular beads is given in the 
Supplementary Information file. Table I summarizes the bead compositions.















CA/PVP10000/HPMC15000 1 2 15 20
CA/PVP10000/HPMC15000 2 2 5 30




CA/PVP10000/Lactose 2 17.5 17.5
Thermogravimetric analysis
A TA Instrument Q500 TGA Analyzer was utilized for the thermogravimetric analysis 
(TGA) experiments, in the temperature range of 30–900 °C, at a heating rate of 10 °C min–1 in 
an air atmosphere. Dry beads were weighed directly into the TGA pan.
Entrapment efficiency
The MLT Entrapment Efficiency (EE%) of the beads was calculated by measuring the 
absorbance of the supernatant solution obtained from the entrapment medium after cen-
trifugation (Sigma 3-0KS, Germany), employing a Perkin-Elmer UV spectrophotometer 
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(Norwalk, CT) at 278 nm and determining the EE% from Equation 1. MLT concentration 
was determined from the MLT standard plot.
 EE% = Total melatonin added – Nonentrapped melatonin × 100
Total melatonin added
 (1)
Swelling studies and measurements
The beads were spread on aluminum foil and dried at 40 °C overnight in an oven 
(WTB B34 Binder GmbH, Germany). Dry beads were used for the swelling studies. The 
swelling experiments were performed in two discrete dispersion media, in accordance 
with the reported protocols (26, 27). Full experimental details are given in the Supplemen-
tary Information file.
The dynamic mass change (%) of the beads with respect to time was calculated accord-
ing to Equation 2:







where mt is the mass of the swollen beads and mi is their initial mass.
MLT release studies
A USP XXII dissolution apparatus II (Pharma test, Germany) (paddle method) was 
employed for determining MLT’s release from the prepared formulations. The beads were 
placed into two different media simulating, in subsequent order, the stomach and the 
 enteric environment. At the end of the first phase (450 mL HCl (1 mol L–1), pH 1.2 for the 
first 120 min), a solution of 450 mL K2HPO4 (0.14 mol L
–1), pH 9, was added to acquire the 
desired composition of the next phase (final volume 900 mL, pH 6.8) and the resulting 
mixture was maintained at a controlled temperature of 37.0 ± 0.5 °C. The paddles’ rotation 
was set at 50 rpm. At each time point, the samples were removed and replaced with an 
equal volume of fresh medium. The concentration of MLT released into the medium was 
recorded using a Perkin-Elmer UV spectrophotometer (USA), at a wavelength of 278 nm.
Release kinetics
In order to decipher the drug release mechanisms, the dissolution test results were 





=   (3)
where Mt/M¥ is the fraction of drug released at time t, k is the constant related to the 
structural and geometric characteristic of the device, and n is the release exponent, indi-
cative of the drug release mechanism. The k and n values were measured up to the initial 
40 % release of the drug. In the case of spheres, values of n between 0.43 and 0.85 are indi-
cative of both diffusion-controlled drug release and swelling controlled drug release. Val-
ues higher than 0.85 indicate Case-II transport, which during gel swelling, is related to 
polymer relaxation (28, 29).
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In order to compare the dissolution profiles, graphs of MLT (%) release (mean ± SD) vs. 
time were produced and the Dissolution Efficiency (DE%) (30) was calculated. 
Initially, descriptive statistics were applied to the swelling and DE% data. The normal-
ity of distribution was assessed using the nonparametric Shapiro-Wilk test and QQ plots. 
Based on these results, the parametric one-way analysis of variance (ANOVA) was applied 
separately to the swelling and DE% data using the term ‘Formulation’ as a grouping factor. 
Post hoc tests, using the Tukey statistic, were also performed to identify potential differ-
ences between the formulations. In all analyses, the significance limit was set at 5 % (i.e., p 
= 0.05). The entire analysis was implemented in IBM SPSS v.24 (IBM Corp, USA).
RESULTS AND DISCUSSION
Thermogravimetric analysis
The degradation process of CA and their hybrid analogues is depicted in Fig. 1. A  certain 
pattern of seven degradation processes and one plateau is observed in all thermogravimetry 
graphs, with differences in the temperature range for each sample. The first degradation is 
observed in the range of 30–200 °C, which is due to the loss of physisorbed and chemisorbed 
water molecules. The second three-step degradation process occurs in the 190–220 °C, 
 220–260 °C and 260–290 °C temperature ranges resulting in a 40–45 % mass loss, due to the 
elimination of hydroxyl groups and alginate backbone degradation (31). These procedures 
were slightly transposed to higher temperatures for the CA/HPMC samples. They also pres-
ent two more degradation processes at the temperature range of 350–380 °C and 380–500 °C, 
that are due to the melting and degradation of HPMC, respectively (32). The CA/PVP sam-
ples follow the same degradation path as the plain CA samples in the temperature range of 
30–400 °C. A slight differentiation for the CA/PVP55000 sample is noticed in the range of 
300–400 °C since it exhibits a 4 % mass loss in comparison with the CA/PVP15000 sample. The 
Fig. 1. Thermogravimetric analysis curves for all calcium-alginate beads (CA – calcium alginate, 
HPMC – hydroxypropylmethylcellulose, PVP – polyvinylpyrrolidone). The axes denote the mass 
change (%) vs. temperature (oC).
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further temperature increase in the range of 400–500 °C leads to a 20 % mass loss for both 
CA/PVP samples, due to the full degradation of the PVP polymer (33). The CA/MLT and the 
CA/Lactose samples present a two-step process in the range of 300–500 °C, with an observed 
mass loss of 18 % for CA/MLT and 20 % for CA/Lactose respectively, depicting the decom-
position of MLT and lactose (34). The final degradation process for the CA sample occurs in 
the region of 650–750 °C and is a result of decarboxylation and the formation of calcium 
oxide and calcium hydroxide (31). On the other hand, a certain hysteresis of the latter 
 phenomenon is observed for the hybrid samples, bringing the particular process at higher 
temperatures of at least 50 °C. More specifically, the CA/PVP10000 and the two CA/HPMC 
samples present the final two-step decomposition at 700 °C, while the final one-step  CA/MLT, 
CA/Lactose and CA/PVP55000 degradation takes place at 750 °C.
Entrapment efficiency of MLT beads (EE%)
The EE% values obtained for all beads’ formulations, containing 2 mg of MLT, were 
similar, as shown in Table II. In all cases the rate of EE exceeded 78 %, showing that the 
method followed for the entrapment of MLT in the beads is effective.
Table II. Entrapment of MLT in different formulations (EE%)
Formulation Entrapment efficiency (EE%)
CA/MLT 78.83 ± 1.04
CA/PVP10000 82.17 ± 1.61
CA/HPMC15000 78.67 ± 1.44
CA/PVP10000/HPMC15000 1 78.83 ± 2.08
CA/PVP10000/HPMC15000 2 79.00 ± 1.32
CA/PVP55000/HPMC15000 79.17 ± 1.53
CA/PVP55000 79.50 ± 10.50
CA/HPMC100000 78.17 ± 0.76
CA/Lactose 79.17 ± 1.04
CA/PVP10000/Lactose 81.83 ± 1.04
The indicated values are the mean of 3 measurements ± SD.
Swelling studies
The swelling profile of the dry beads in SGF (< 2 h), and in SIF, thereafter, is demon-
strated in Fig. 2. The swelling of the biopolymers is presented in the graphs of mass change 
(%) vs. time; the swelling was found to be dependent on the aqueous medium. The CA 
containing beads swell considerably in SGF (pH = 1.2) and to a lesser extent in the SIF 
(pH = 6.8) medium. The increase in the beads’ mass reaches ~350 %. This increase is due to 
the hydration of the carboxylic acid functional groups (35).
The descriptive statistical criteria of swelling at 180 min are listed in Table S1 in the 
supplementary information. Further analysis of swelling (at 180 min) resulted in statistical 
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significant differences (p < 0.05) among all pairs of formulations (Table S2) except from the 
following: CA/PVP10000 vs. CA/PVP55000, CA/PVP10000 vs. CA/PVP10000/Lactose, CA/
HPMC15000 vs. CA/PVP55000/HPMC15000, CA/PVP10000/HPMC15000 vs. CA/HPMC100000, and 
CA/PVP55000/HPMC15000 vs. CA/HPMC15000.
MLT release studies
It is evident, from the MLT loaded hydrogel CA beads swelling data that the extent of 
their expansion is pH-dependent and related to the nature and the molecular mass/viscosity 
of the biopolymer used (Fig. 2). Thus, the MLT beads containing HPMC100000 showed the 
highest swelling (formulation CA/HPMC100000), which was followed by their congeners 
containing HPMC 15000 (formulation CA/HPMC15000). The same trend was observed, but 
to a lesser extent, in the case of the PVP containing MLT beads (formulation CA/PVP55000 
vs. formulation CA/PVP10000). The lactose monohydrate MLT beads (formulation CA/Lac-
tose) swelled less than all the above systems. It is well documented that the higher the 
molecular mass/viscosity of HPMC and PVP the higher their swelling due to the thicker 
gel they form, when in contact with aqueous media (36, 37).
The release of MLT from the beads was found to be reversibly proportional to the 
molecular mass/viscosity of the HPMC hydrogels they contain (Fig. 3). Thus, in the acidic 
pH medium, the release of MLT from the HPMC15000 beads is substantially higher (formu-
lation CA/HPMC15000 97.03 % at t = 120 min) than the respective release from the HPMC100000 
containing beads (formulation CA/HPMC100000 86.87 % at t = 120 min). A similar MLT 
 release profile emerged and in the case of the different molecular mass/viscosity PVP con-
taining beads (formulation CA/PVP10000 93.24 % at t = 60 min vs. formulation CA/PVP55000 
73.37 % at t = 60 min). At pH 6.8, the same trend was observed in both the HPMC and PVP 
Fig. 2. Swelling profiles of dry beads at pH 1.2 for the first two hours and at pH 6.8, thereafter. The 
results denote the mean ± S.D. (n = 3) (CA – calcium alginate, HPMC – hydroxypropylmethylcellulose, 
PVP – polyvinylpyrrolidone).
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cases, but it is of no practical meaning as almost the entire amount of MLT was already 
released in the acidic pH medium, at t ≤ 120 min.
Moreover, from the mechanistic point of view at a molecular level, and besides the 
influence of the extent of swelling caused by the two different types of HPMC, present in 
the beads, on MLT’s release, the fact that a large number of HPMCs CH2OH groups are 
methylated, reduces the ability of these hydrogels to form hydrogen bonds with MLT’s 
C5-OMe. This results in the reduced solubility of the hormone noticed in this case.
Conversely, the facile solubilization of MLT from the PVP containing CA beads can be 
attributed to the conversion of PVP (II) to the gem-diol (III), at pH 1.2 (38). The hydroxyl 
groups of III participate in H-bond formation with MLT’s C5-oxygen atom and the 
NHCOCH3 group, thus facilitating its aqueous solubility.
With respect to the release kinetics, it was found that the release of MLT in the case of 
formulations 1 and 9 followed a Fickian diffusion mechanism (n = 0.31). The value of the 
diffusion coefficient (n = 0.53), in the case of the CA/HPMC100000 formulation, is an indica-
tion of both diffusion-controlled drug release and swelling-controlled drug release kinetics 
(anomalous transport). The diffusion coefficient n values could not be calculated in all 
other cases, as the release exceeded 60 %, at cca t = 30 min.
The extent of the expansion of the CA beads containing mixtures of hydrogels (for-
mulations CA/PVP10000/HPMC15000 1, CA/PVP10000/HPMC15000 2, CA/PVP55000/HPMC15000 
and CA/PVP10000/Lactose) was found to depend on the nature of the respective biopoly-
mers and their relevant concentration in the mixtures. Thus, the least bead expansion was 
Fig. 3. In vitro MLT release from different CA beads formulations. The results denote the mean ± S.D. 
(n = 3) (CA – calcium alginate, HPMC – hydroxypropylmethylcellulose, PVP – polyvinylpyrrolidone).
535
M. Vlachou et al.: Probing the release of the chronobiotic hormone melatonin from hybrid calcium alginate hydrogel beads, Acta Pharm. 
70 (2020) 527–538.
 
seen in the case of formulation CA/PVP10000/Lactose, where the moderately swelling pro-
moter, lactose monohydrate, was co-present with PVP10000, in the mixture, in the same 
amount (17.5 mg). A high bead’s expansion was noticed in the case of formulation CA/
PVP10000/HPMC15000 2, where HPMC15000 (30 mg) was mixed with a smaller amount of 
PVP10000 (5 mg). Even higher was the expansion of the beads of formulation CA/PVP55000/
HPMC15000, as these were prepared by mixing 5 mg of PVP55000 and 30 mg of HPMC15000. 
The formulation CA/PVP10000/HPMC15000 1, CA beads, containing HPMC15000 (20 mg) and 
PVP10000 (15 mg) swelled more than all the rest mixture beads composites.
Once again, the release of MLT was affected by the relevant concentration and nature 
of the hydrogels in the mixture. Thus, in the acidic pH medium the release of MLT from 
formulation CA/PVP10000/HPMC15000 2 (30 mg of HPMC15000 and 5 mg of PVP10000) is much 
lower (66.73 %) than from formulation CA/PVP10000/HPMC15000 1 (20 mg HPMC15000 and 
15 mg PVP10000). An analogous MLT release pattern was observed in the case of formulation 
CA/PVP55000/HPMC15000 (30 mg of HPMC15000 and 15 mg of PVP55000). These differences in the 
release of MLT from mixtures of biopolymers is more profound in the case of formulation 
CA/PVP10000/Lactose, where MLT is entrapped in lactose monohydrate and PVP10000 con-
structed beads. In this case, the release of MLT reached 100 % at t = 90 min. In the pH 6.8 
medium, at t ≥ 120 min, an analogous MLT release pattern was observed.
As it was previously mentioned, we aimed at designing and developing dosage forms, 
which mimic the physiologically secreted high MLT levels at night, necessary to promote 
sleep onset and maintain sleep. From the results obtained from the release studies, it be-
came apparent that in all cases, MLT released from the prepared beads (40–80 %) during 
the first 30 min. This release profile is useful for the promotion of sleep. In other words, 
insomniacs may use the particular dosage form 30 min before bedtime. Moreover, the re-
maining MLT quantity is released within the next 3 h, and thus these formulations are also 
useful in maintaining sleep.
Table S3 lists the descriptive statistical criteria of DE%. Additional statistical analysis 
of the DE% values among the various formulations is presented in Table S4 (Supplemen-
tary Information). 
CONCLUSIONS
Several hybrid CA hydrogel beads containing polymeric biomaterials and MLT as the 
active pharmaceutical ingredient have been produced and studied. It was shown that the 
right choice of common polymeric hydrogels, in terms of the nature of the polymer, its 
molecular mass and the composition for the preparation of CA MLT beads, determines the 
encapsulation and swelling properties of the hybrid beads. The successful formulations 
may be effectively used for treating circadian rhythm desynchronization disorders. As a 
result, these MLT formulations can either treat sleep onset or poor sleep maintenance  related 
problems.
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